Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 2/20 | 0.35 |
| ▸ | BRS3 | P32247 | 8/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9709582 | 0.83 | IAPP (0.39) | FFAR1AGTR1LTB4R2 | |
| SCHEMBL9709552 | 0.80 | IAPP (0.40) | BRS3FFAR1AGTR1AGTR2LTB4R2 | |
| SCHEMBL6956494 | 0.80 | TDP1 (0.40) | BRS3 | |
| SCHEMBL9709753 | 0.78 | LTB4R2 (0.42) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL6949584 | 0.77 | LTA4H (0.37) | HSD11B1BRS3AGTR1AGTR2 | |
| SCHEMBL9709732 | 0.77 | LTB4R2 (0.41) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL1773521 | 0.77 | FYN (0.39) | AGTR1AGTR2 | |
| SCHEMBL8698309 | 0.76 | MLYCD (0.47) | AGTR1LTB4R2 | |
| SCHEMBL6960893 | 0.76 | CA2 (0.35) | HSD11B1BRS3AGTR1AGTR2 | |
| SCHEMBL6961100 | 0.76 | NPC1 (0.39) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5157040-A | Treatment of hypertension, ocular hypertension and some CNS disorders | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0507594-A1 | Substituted quinolines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-10-07 | — | — | EP | disclosed |